AUA 2023: Dr. Stratton discusses prostate cancer research

In this video, Kelly L. Stratton, MD, FACS, recaps several presentations from the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.

The following research/presentations are discussed:

1. Panel Discussion: Triple Therapy vs. Chemotherapy/ADT for Newly Diagnosed mHSPC Patients (Treatment intensification)

2. MP29-01 (Saad et al): Rapid, durable, and deep prostate-specific antigen response following addition of darolutamide to androgen-deprviation therapy and docetaxel in ARASENS

3. LBA02-09 (Shore et al): EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer

4. Debate: Renaming Gleason 6 Prostate Cancer

5. Advanced Prostate Cancer: AUA/SUO Guideline (2023)